Fingolimod Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/08/2023 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
amended 
on 
SmPC, Annex 
II and PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IAIN/0006/G 
This was an application for a group of variations. 
12/05/2023 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0005 
B.III.1.a.1 - Submission of a new/updated or 
27/02/2023 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0004/G 
This was an application for a group of variations. 
08/02/2022 
08/07/2022 
SmPC 
To update sections 4.4, 4.8, 5.1 and 5.2 due to the same 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
changes being adopted for parent product Gilenya following 
assessment of the non-interventional final study report 
D2403 (long-term, prospective, multinational, parallel-
cohort study monitoring safety in patients with multiple 
sclerosis newly started on fingolimod once daily or treated 
with another approved disease-modifying therapy). 
Consequently, the Annex IID is updated to remove the 
obligation to perform the PASS D2409. 
An updated RMP has been also provided. 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/1393/
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
202102 
fingolimod 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
26/07/2021 
08/07/2022 
SmPC and PL 
To update subsections of Infections, Liver injury and 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Hepatobiliary disorders with a frequency not know (acute 
hepatic failure) following the safety assessment of the 
same change for the reference product. 
Page 3/3 
 
 
 
 
 
 
 
 
 
